BioMarin’s $270M Inozyme Acquisition Brings Drug That Could Become First for a Rare Disease

Inozyme Pharma’s main asset is in pivotal testing in children who have a rare enzyme deficiency that affects bones and blood vessels. BioMarin Pharmaceutical, already well established in enzyme replacement, said it will use its experience and infrastructure to grow the market for this product, potentially for several indications. The post BioMarin’s $270M Inozyme Acquisition…

Read More

State-Level Context for Federal Medicaid Cuts of $625 Billion and Enrollment Declines of 10.3 Million

Based on draft reconciliation language from the Energy & Commerce Committee, the Congressional Budget Office (CBO) released preliminary estimates showing proposed Medicaid changes would reduce federal Medicaid spending by $625 billion. Building on earlier KFF analysis, this analysis puts this magnitude of federal funding cuts into context by showing how the cuts relate to states’…

Read More

Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis

Breakthroughs in synthetic biology could help accelerate advances in applications from novel infectious disease vaccines, precision immunotherapy for cancer and antibody therapeutics to creation of engineered meat substitutes and sustainable cellular agricultural products. The post Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis appeared first on MedCity News.

Read More